Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kobayashi Pharmaceutical Co's quarterly Accounts Payable
declined
from Dec. 2025 (円8,458 Mil) to Mar. 2026 (円7,684 Mil) but then
increased
from Mar. 2026 (円7,684 Mil) to Jun. 2026 (円7,891 Mil).
Kobayashi Pharmaceutical Co's annual Accounts Payable
declined
from Dec. 2023 (円8,745 Mil) to Dec. 2024 (円8,264 Mil) but then
increased
from Dec. 2024 (円8,264 Mil) to Dec. 2025 (円8,458 Mil).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kobayashi Pharmaceutical Co Accounts Payable Chart
Kobayashi Pharmaceutical Co Accounts Payable Calculation
Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.
Kobayashi Pharmaceutical Co (TSE:4967) has a Accounts Payable of 円7,891 Mil as of Jun. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Kobayashi Pharmaceutical Co and its competitors.
Is Kobayashi Pharmaceutical Co's Accounts Payable too high?
Kobayashi Pharmaceutical Co's current Accounts Payable is 円7,891 Mil. Overall, Kobayashi Pharmaceutical Co has a GF Score™ of 79/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kobayashi Pharmaceutical Co's Accounts Payable compare to PG and CL?
Kobayashi Pharmaceutical Co's Accounts Payable of 円7,891 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Consumer Packaged Goods company?
A good Accounts Payable depends on the Consumer Packaged Goods industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Kobayashi Pharmaceutical Co and its competitors. Kobayashi Pharmaceutical Co's current Accounts Payable is 円7,891 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kobayashi Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Kobayashi Pharmaceutical Co (TSE:4967) is currently considered Modestly Overvalued. The stock's GF Value™ is 円4,935.61, compared to a current price of 円5,700.00 — trading 15.5% above its estimated fair value. The current Accounts Payable is 円7,891 Mil. Kobayashi Pharmaceutical Co's overall GF Score™ is 79/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Kobayashi Pharmaceutical Co (TSE:4967), the current Accounts Payable is 円7,891 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kobayashi Pharmaceutical Co (TSE:4967) Overvalued in 2026?
Based on GuruFocus' analysis, Kobayashi Pharmaceutical Co stock appears to be overvalued.
The current stock price of 円5,700.00 is trading 15.5% above its estimated GF Value™ of 円4,935.61.
GuruFocus considers Kobayashi Pharmaceutical Co to be Modestly Overvalued.
Key valuation signals for TSE:4967:
Accounts Payable: 円7,891 Mil
GF Value™: 円4,935.61 vs. price of 円5,700.00 (15.5% above fair value)
No single metric tells the full story. See the TSE:4967 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kobayashi Pharmaceutical Co Ltd is engaged in the manufacture and sale of healthcare products, daily necessities, and body warmers. The company operates through two reportable segments: Domestic Business and International Business, which handle production and sales activities in Japan and overseas, respectively. The company's product portfolio includes disposable body warmers, cooling gel sheets, OTC pharmaceuticals, oral hygiene products, air fresheners, eyeglass wipes, and deodorizing/household sundries.
79GF Score
Get the complete analysis for TSE:4967
Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4967 has been successfully added to your 
